Products for Research Use Only

Dacarbazine-d6

CAT: 0804-HY-B0078SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0078SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Dacarbazine-d6 is the deuterium labeled Dacarbazine. Dacarbazine (DTIC-Dome; DTIC) is an antineoplastic agent. It has significant activity against melanomas.
CAS Number
1185241-28-4
Product Name Alternative
Imidazole Carboxamide-d6
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Apoptosis; Isotope-Labeled Compounds; Nucleoside Antimetabolite/Analog
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Others
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
[2H]C([2H])([2H])N(C([2H])([2H])[2H])/N=N/C1=C(N=CN1)C(N)=O
Molecular Formula
C6H4D6N6O
Molecular Weight
188.22
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Serrone, L., et al., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res, 2000. 19 (1) : p. 21-34.|[3]Ramanathan, R.K., et al., Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol, 2001. 12 (8) : p. 1139-43.|[4]Middleton, M.R., et al., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol, 2000. 18 (1) : p. 158-66.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported